Overview

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Rampart Health, L.L.C.
Treatments:
Cyclophosphamide
Ipilimumab
Nivolumab